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Sex Med 2Introduction: The Sexual Health Outcomes in Women Questionnaire (SHOW-Q) is designed to evaluate the
sexual life of women for satisfaction, orgasm, desire, and pelvic problem interference. The SHOW-Q is
important for evaluating worsening of sexual life for patients with pelvic problems and the management of these
women to improve their sexual life.
Aims: To validate the Turkish versions of the SHOW-Q for Turkish-speaking women.
Methods: The Turkish version of the SHOW-Q was generated by two independent professional English-to-
Turkish translators. The translated version of the SHOW-Q was reverse translated by two bilingual trans-
lators whose native language was English. Women with at least one symptom related to pelvic problems (n ¼ 71)
and those with no symptoms (n ¼ 38) were included in the present study.
Main Outcome Measures: Test-retest reliability analysis, content-face validity, internal consistency reliability,
item-total correlations, convergent validity, construct validity, and factorial validity were performed to assess the
psychometric properties of the Turkish versions of the SHOW-Q.
Results: Test-retest reliability demonstrated good correlation for all subscales. Cronbach a values ranged from
0.735 to 0.892 and indicated high internal consistency. There was a strong correlation for the corresponding
subscales between the SHOW-Q and the Female Sexual Function Index. The mean score of each SHOW-Q
subscale showed signiﬁcant differences between symptomatic and asymptomatic patients.
Conclusion: The Turkish version of the SHOW-Q is a valid and reliable instrument that can be used to evaluate
the sexual life of Turkish-speaking women with different pelvic problems.
Sex Med 2016;4:e91ee96. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the International
Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Female sexual dysfunction (FSD) is a frequent complaint in
women of all ages and the prevalence of FSD has been reported
at 19% to 45% in epidemiologic studies.1 The importance of
FSD has been related to its signiﬁcant effect in worsening
women’s quality life.2,3vember 24, 2015. Accepted January 7, 2016.
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016;4:e91ee96Despite the detrimental effect of FSD on quality of life and its
high prevalence, most women who have FSD do not report their
problems to their physicians.4 In addition, the sexual life of
patients is typically investigated inadequately in busy clinical
settings. The use of a validated, condition-speciﬁc questionnaire
instead of direct questioning about their sexual life could allow
women to be more comfortable expressing their complaints.
Physical and psychosocial factors have been the main reported
causes of FSD. Physical factors consist mainly of pelvic problems
that can manifest as abnormal uterine bleeding (AUB), pelvic
pain, and dyspareunia related to various gynecologic pelvic dis-
orders.5 The reported prevalences of dysmenorrhea, dyspareunia,
and pelvic pain are 90%, 46%, and 39%, respectively. AUB is a
signiﬁcant factor in the deterioration of the quality of women’s
sexual life, with an annual prevalence rate of approximately 53.0e91
e92 Selcuk et alper 1,000 women.6,7 Similarly, different studies have demon-
strated the relation between pelvic pain and sexual dysfunction.
More than two thirds of women with chronic pelvic pain have
sexual problems related to pain symptoms.8,9
The Sexual Health Outcomes in Women Questionnaire
(SHOW-Q) was developed by Learman et al10 in 2008. This
questionnaire is designed to assess the sexual life of women for
satisfaction, orgasm, desire, and pelvic problem interference. The
SHOW-Q is important for evaluating the worsening sexual life
of patients from pelvic problems and the management of these
women to improve their sexual life. To our knowledge, there is
no speciﬁc Turkish questionnaire for evaluating the effect of
various pelvic problems on women’s sexual life.
AIMS
The aim of present study was to validate the Turkish version
of the SHOW-Q for Turkish-speaking women.
METHODS
Patients and Study Design
This prospective case-control study included 120 women
attending our outpatient clinic for different gynecologic problems
or routine annual gynecologic examination. Eleven women (nine
without symptoms and two with symptoms) refused to participate
in the study. Therefore, 109 women were eligible for the study.
The local research and ethics committee of our hospital approved
the study protocol. An informed consent form was obtained from
all patients. Women were evaluated for symptoms related to gy-
necologic pelvic disorders. Gynecologic examination and pelvic
ultrasonography were performed on all patients. Women with at
least one of the pelvic problems listed inTable 1were categorized as
symptomatic and women without any of those problems were
categorized as asymptomatic. The pelvic problems listed in Table 1
were deﬁned and limited according to the symptoms present in the
questionnaire. Exclusion criteria were sexually inactive women,
women with general or genital symptoms other than the investi-
gated symptoms, and women who declared sexual dysfunction for
their partners. All patients with SHOW-Q scores indicating
worsening of their sexual function were advised to visit a psychi-
atrist who specialized in sexual function disorders.
Translation and Culture Adaptation
Two independent professional English-to-Turkish translators
generated the Turkish version of the SHOW-Q. The translatedTable 1. Pelvic symptoms of the women in this study
Symptoms % (n)
Abnormal uterine bleeding 28.4 (31)
Non-cyclic chronic pelvic pain 31.2 (34)
Dysmenorrhea 49.5 (54)
Dyspareunia 34.9 (38)
No symptoms 34.9 (38)version of the SHOW-Q was reverse translated by two bilingual
translators whose native language was English. There was no
inconsistency between the original and reverse-translated ver-
sions of the SHOW-Q. The Turkish version of the SHOW-Q
included several alternatives for controversial items and answer
choices. Then, the independent translators and two Turkish
physicians familiar with the terminology of sexual functions and
quality of life produced the second Turkish version of the
SHOW-Q after completing the required revisions. Fifteen
women were asked to self-complete the second version of the
SHOW-Q and discuss the ambiguous questions. Eventually,
the Turkish version of the SHOW-Q was developed and
completed.
Test-retest reliability and internal consistency analyses of the
Turkish form of the SHOW-Q were assessed with a pilot study.
To assess the test-retest reliability of the ﬁnal Turkish version of
the SHOW-Q, a 2-week test-retest analysis was used. Twenty
women were asked to complete the questionnaire at the ﬁrst
examination and the same women completed the questionnaire 2
weeks later. Spearman correlation was used to analyze the an-
swers of the two completed questionnaires. Women who refused
to complete the questionnaire were excluded from the study.
Questionnaire
The SHOW-Q included 12 items and 4 subscales: satisfaction
(2 items), orgasm (4 items), desire (3 items), and pelvic problem
interference (3 items). Women were asked to answer the ques-
tions in relation to the previous 4 weeks. All items were scored on
a scale from 0 to 100. For the ﬁrst three subscales (satisfaction,
orgasm, and desire), higher scores represent better sexual func-
tion; for the fourth subscale (pelvic problem interference), higher
scores represent worse sexual function.
All patients were asked to complete the validated Turkish
version of the Female Sexual Function Index (FSFI).11 The FSFI
is a self-report questionnaire that includes 19 items and 6 sub-
scales that evaluate desire, subjective arousal, lubrication, orgasm,
satisfaction, and pain during the previous months.12 Each sub-
scale is scored from 0 to 6 and higher scores in each subscale
indicate better sexual function. The total score of the question-
naire ranges from 2 to 36.MAIN OUTCOME MEASURES
Test-Retest Reliability Analysis
Spearman correlation was performed for test-retest reliability,
which was used to assess the stability and reliability of the
questionnaire. A Spearman r value higher than 0.8 denoted high
reliability.13Content-Face Validity
The content-face validity, which indicates whether the
questionnaire makes sense to the patients and experts and
whether all important and relevant domains are included, wasSex Med 2016;4:e91ee96
Table 2. Demographic and clinic data of the groups in this study
Asymptomatic Symptomatic
Translation and Validation of the SHOW-Q e93assessed by an expert panel that included two gynecologists and
one psychometrician.patients
(n ¼ 38)
patients
(n ¼ 71) P value
Age (y)* .332
Mean ± SD 34.16 ± 6.55 32.67 ± 6.75
Minimum-maximum 25-52 20-48Internal Consistency
Cronbach a statistical analysis was used to assess the internal
consistency of each subscale and a value higher than 0.70 indi-
cated sufﬁcient internal consistency for each subscale.13Gravida* .537
Mean ± SD 1.63 ± 1.64 1.39 ± 1.38
Minimum-maximum 0-5 0-5
Parity* .634
Mean ± SD 1.24 ± 1.36 1.07 ± 1.71Item-Total Correlations
Item-total correlations evaluated the degree of linear relation
between an item and its total score (corrected for overlap). A
correlation coefﬁcient higher than 0.40 denoted good item-total
consistency.14Minimum-maximum 0-5 0-4
BMI (kg/m2)* .062
Mean ± SD 25.52 ± 3.08 24.60 ± 5.69
Minimum-maximum 19.5-33.1 16.2-44.1
Education level, n (%)† .860
Primary school 16 (42.1) 35 (50.7)
High school 13 (34.2) 20 (29.0)
University 9 (23.7) 14 (20.3)
Marital status, n (%)† .410
Married 33 (86.8) 64 (90.1)Convergent Validity
The validated Turkish version of the FSFI was used to evaluate
the convergent validity of the SHOW-Q. Signiﬁcant correlations
were found between the SHOW-Q satisfaction subscale and the
FSFI satisfaction subscale, between the SHOW-Q orgasm sub-
scale and the FSFI orgasm subscale, between the SHOW-Q
desire subscale and the FSFI desire subscale, and between the
SHOW-Q pelvic problem interference subscale and the FSFI
pain subscale. The Spearman correlation coefﬁcient (r) was used
for all correlations between subscales.Single 5 (13.2) 7 (9.9)
Menopause, n (%)† 3 (7.9) 2 (2.8) .227
BMI ¼ body mass index.
Signiﬁcant at P ¼ .05 by *Mann-Whitney U-test and †c2 test.Construct Validity
Construct validity demonstrates the value of a questionnaire in
discriminating patients with from those without symptoms and it
was evaluated by comparing the SHOW-Q scores of women
with and without a pelvic problem listed in Table 1.13Factorial Validity
To verify the factor structure of the SHOW-Q subscales,
principal component factor analysis with varimax rotation was
performed. Items with a value of at least 0.30 on principal
components analysis were retained for factor analysis.
The Turkish version of the SHOW-Q is available by request
from the ﬁrst author.Statistical Analysis
Statistical analyses were performed using SPSS 15.0 (SPSS,
Inc, Chicago, IL, USA). The Mann-Whitney U-test and c2
test were used where appropriate. The level of signiﬁcance was
set at a P value equal to .05 level and all P values were
two-tailed.RESULTS
Of 109 patients included in this study, 65.1% (n ¼ 71) had at
least one symptom related to pelvic problems, whereas 34.9%
(n ¼ 38) did not have such symptoms (Table 1). The socio-
demographic characteristics of all patients are listed in Table 2.Sex Med 2016;4:e91ee96All patents were sexually active. There was no signiﬁcant dif-
ference in sociodemographic characteristics between the symp-
tomatic and asymptomatic groups.
In the test-retest reliability analysis, all subscales showed sta-
tistically signiﬁcant correlation and Spearman r values ranged
from 0.836 to 0.892.Item-Total Correlation and Internal Consistency
The outcomes of corrected item-total correlation and internal
consistency of the SHOW-Q are presented in Table 3. Item-total
correlations of all subscales were higher than the required min-
imum level of 0.40 and those demonstrated good internal con-
sistency for items. Cronbach a value for the translated form of
the 12-item scale of the SHOW-Q was 0.847 and demonstrated
good internal reliability. Cronbach a levels of all subscales ranged
from 0.735 to 0.892 and were higher than the acceptable min-
imum a coefﬁcient of 0.70.Convergent Validity
All corresponding subscales of the SHOW-Q and the FSFI
showed signiﬁcant correlation. Spearman r values are listed
in Table 4. Orgasm subscales of the SHOW-Q and the
Table 3. Corrected item-total correlation and internal consistency
of Sexual Health Outcomes in Women Questionnaire
Items
Corrected
item-total
correlation
Satisfaction scale (a ¼ 0.892, n ¼ 109)
How satisﬁed have you been with the frequency
of your sexual activity (with or without a
partner)?
0.807
How satisﬁed in general have you been with
your ability to have and enjoy sex (with or
without a partner)?
0.807
Orgasm scale (a ¼ 0.817, n ¼ 109)
When you had sexual activity, how much of
the time did you experience orgasm?
0.701
When you had sexual activity, how much of
the time did you feel satisﬁed after sexual
activity?
0.669
When you experienced orgasm, how strong
or intense was the orgasm on average?
0.675
How much of a problem was difﬁculty in
having an orgasm?
0.545
Desire scale (a ¼ 0.735, n ¼ 109)
How much of a problem was lack of sexual
interest?
0.699
How often did you desire sex (with or without
a partner?)
0.427
How much of a problem was the inability to
relax and enjoy sex?
0.569
Pelvic interference scale (a ¼ 0.848, n ¼ 109)
To what extent has your bleeding interfered
with your normal or regular sexual activity
(with or without a partner)?
0.542
To what extent has your pelvic pain or
discomfort interfered with your normal
or regular sexual activity (with or without
a partner)?
0.801
To what extent have your pelvic problems
overall interfered with your normal or regular
sexual activity (with or without a partner)?
0.831
Table 4. Correlation between similar subscales of the SHOW-Q
and the FSFI
SHOW-Q FSFI Spearman r*
Satisfaction Satisfaction 0.635†
Orgasm Orgasm 0.724†
Desire Desire 0.540†
Pelvic interference Pelvic pain 0.535†
FSFI ¼ Female Sexual Function Index; SHOW-Q ¼ Sexual Health Out-
comes in Women Questionnaire.
*Two-tailed test.
†P < .001.
e94 Selcuk et alFSFI showed the strongest correlation (Spearman r ¼ 0.724,
P < .001).Construct Validity
Patients were grouped as symptomatic and asymptomatic. The
scores of all subscales showed statistically signiﬁcant differences
between the two groups. The mean scores of satisfaction, orgasm,
and desire subscales were signiﬁcantly higher, whereas the mean
scores of the pelvic problem interference subscale were signiﬁ-
cantly lower, in the asymptomatic group (Table 5). These results
showed that the sexual life of patients without symptoms was
better than that of symptomatic patients.Factorial Validity
Using varimax rotation, we found that the four domains of the
SHOW-Q could be divided into two constructs or components
(Table 6). The ﬁrst construct consisted of satisfaction, orgasm,
and desire. The second construct consisted of pain.DISCUSSION
Linguistic validation studies verify the validity and reliability
of the translated version of the questionnaire for culturally
different populations. When a questionnaire is translated into
another language, semantic shifts of some speciﬁc terms related
to item assessment might occur because of cultural variability in
different populations. Test-retest reliability analysis, content-face
validity, internal consistency reliability, item-total correlations,
convergent validity, construct validity, and factorial validity were
used to assess the psychometric properties of this translated
questionnaire.
In this study, Spearman r values of all subscales indicated
high test-retest reliability. The Cronbach a value for each item
and subscale (range ¼ 0.735e0.892) demonstrated high in-
ternal consistency reliability and the results were consistent with
the original study by Learman et al10 In addition, item-total
correlations of all items exceeded the required minimum level
of 0.40 and those showed good internal consistency for all
items.
Convergent validity was performed with correlation analysis of
similar subscales of the SHOW-Q and validated Turkish version
of the FSFI. The FSFI was preferred because its subscales
matched all subscales of the SHOW-Q, allowing a convergent
validation. Each subscale of the SHOW-Q highly correlated with
the corresponding subscale of the FSFI and these correlations
conﬁrmed the convergent validity of the Turkish version of the
SHOW-Q.
Construct validity was assessed by comparison of the score of
the each subscale between symptomatic and asymptomatic pa-
tients. Each subscale showed a signiﬁcant difference between the
two groups. These results demonstrated that the Turkish version
of the SHOW-Q scale could discriminate women with from
those without symptoms. Patients with any of these pelvicSex Med 2016;4:e91ee96
Table 5. Sexual Health Outcomes in Women Questionnaire total
score and its subscales in symptomatic and asymptomatic groups
of women
Symptomatic
patients (n ¼ 71),
mean ± SD
Asymptomatic
patients (n ¼ 38),
mean ± SD
P
value*
Satisfaction scale 73.10 ± 20.61 82.11 ± 16.13 .022
Orgasm scale 63.54 ± 17.36 70.32 ± 19.21 .035
Desire scale 66.96 ± 19.39 76.11 ± 16.76 .013
Pelvic interference
scale
49.48 ± 22.84 32.98 ± 13.24 .000
Total 67.90 ± 13.98 78.24 ± 11.71 .000
*Signiﬁcant at P ¼ .05 by Mann-Whitney U-test.
Translation and Validation of the SHOW-Q e95problems scored worse, indicating a lower quality in their sexual
experiences than for those without pelvic problems.
Especially with sexually related questionnaires, assessing the
factorial validity can be of particular importance because the
perception of sexual matters can differ from the societies in
which the original questionnaire was developed.15 Our results
regarding the factorial validity of the Turkish version of the
SHOW-Q demonstrated that its structure is consistent for
Turkish-speaking women.
The SHOW-Q also can be used to evaluate the sexual life of
women without a partner or in same-sex relationships. In our
series, 11.1% of all women had sexual activity without a partner
and no women reported same-sex relationships.
The high prevalence of pelvic problems has been reported in
various studies and AUB, pelvic pain, and dyspareunia are
accepted as common gynecologic disorders in women of all ages.16
In epidemiologic studies, the prevalence of AUB has been reportedTable 6. Factor loadings* of sexual function items on two
components
Domain Items
Component†
1 2
Satisfaction S1 0.742
S2 0.792
Orgasm O3 0.739
O4 0.776
O5 0.751
O6 0.719
Desire D7 0.664
D8 0.495
D9 0.694
Pain P10 0.931
P11 0.914
P12 0.737
*Using principal component analysis with varimax rotation (loadings
< 0.3 are omitted for simplicity).
†Two components were formed using Kaiser’s criteria.23
Sex Med 2016;4:e91ee96as approximately 30% in reproductive-age women.17 Chronic
pelvic pain is the other common gynecologic disorder and the
reported prevalence of chronic pelvic pain ranges from 5.7% to
26.6%.18 The detrimental effect of pelvic problems on the sexual
life of women has been reported in different studies16,19; thus,
symptoms of pelvic problems become a crucial issue in the
assessment of women’s sexual life. In our study, the score on the
pelvic problem subscale, which demonstrates the physical aspects
of sexual life, was signiﬁcantly higher in patients with pelvic
symptoms than in those without these symptoms. Symptomatic
patients had signiﬁcantly worse scores for the satisfaction, orgasm,
and desire subscales, which are related to the psychological do-
mains of sexual life. These ﬁndings indicated that pelvic symptoms
had a detrimental effect on the physical and psychological
domains of sexual functioning. In a study by Di Donato et al,20
the SHOW-Q was used for the assessment of sexual func-
tioning of patients with endometriosis. They reported statistically
signiﬁcant differences in the SHOW-Q total score and each
subscale score between patients with endometriosis and healthy
women. It should be emphasized that pelvic symptoms can cause
impairment in all aspects of sexual functioning such as satisfaction,
orgasm, and desire. Physicians should be aware of the worsening
effect of pelvic problems on sexual life when evaluating patients
with gynecologic pelvic disorders to optimize the management of
this population and improve their quality of life.
Our study has some limitations. The relatively small sample
was caused by the refusal of some patients to participate in the
study. Although the intimate nature of sexual questionnaires can
be embarrassing in any culture, in some cultures, this attitude
can be more pronounced. It has been argued that subjects in such
studies are very reluctant to discuss their sexual problems, which
could clearly distort the study ﬁndings even when this is good
rapport.21 Another possible limitation is that the original
SHOW-Q does not contain any item that evaluates the sexual
partner of a particular patient. The importance of screening the
male partner during clinical assessment of sexual problems in
women is well reported.22 To avoid this inherent limitation of
the SHOW-Q, women who declared sexual dysfunction for their
partners were excluded from the study.CONCLUSION
The SHOW-Q is a relatively brief questionnaire designed to
assess the interference of pelvic problems in the sexual life of
women with various pelvic symptoms. It has been validated in
different clinical conditions. To our knowledge, this is the ﬁrst
linguistic validation study of the SHOW-Q. The present study
showed that the Turkish version of the SHOW-Q is a valid
instrument with adequate reliability for evaluating the sexual life
of Turkish-speaking women with various pelvic problems.
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